Triple Negative Breast Cancer (TNBC) Research Grant

Triple Negative Breast Cancer (TNBC) - defined as estrogen receptor, progesterone receptor and human epidermal growth factor receptor type 2 (HER2) negativity - is heterogeneous with respect to biology, prognosis and response to treatment. TNBC is associated with younger age at diagnosis and with poorer outcomes compared with non-TNBC. Studies to enhance our understanding of TNBC are needed to improve our understanding of its biology and current management and outcome of patients diagnosed with TNBC.

This funding opportunity was made available through a generous philanthropic donation to the UF Health Cancer Center by the Collaboration of Scientists for Critical Research in Biomedicine (CSCRB, Inc.). It recognizes that i) the study of TNBC is underrepresented in academic and industry research portfolios, and ii) there exists a great need to advance our understanding of the genetics and biology of TNBC and for implementing new strategies for clinical trials.

The goals of the TNBC Research Grant are to:
• Identify new research opportunities focused on the biology or treatment of TNBC;
• Create synergies and collaborations within UF Health Cancer Center, the University of Florida, and, if applicable, Orlando Health, UFPTI or other institutions;
• Stimulate applications for future program-type federal or national extramural funding.

The deadline for receipt of applications is: November 17, 2014.

Applications should be submitted to: UF Health Cancer Center, 2033 Mowry Road, Suite 145, PO Box 103633, attn: Belinda Scurlock (email: BScurlock@ufl.edu) and Wendy Malorzo (email: wmalorzo@ufl.edu)

Award Amount and Duration:
1. The award amount is $25,000 per year.
2. The award is for a period of 12 months, with the expectation that all the funds will be expended during that term. There is an option to request a one-time 12 month additional funding, depending on project performance and subject to the availability of funds.
3. Grantees must submit a progress report at six months and again at least 30 days before the end of year one.
4. The grantee will be required to present to CSCRB, Inc., in report form and/or presentation form, on use of the funding and next steps to advance his/her research.
5. Grantees requesting additional funding for year 2 must submit their end-of-year progress report and request for funding at least 45 days before the end of year one. Grants will undergo a comprehensive review of scientific progress.
6. Grants will begin on February 1, 2015.

ELIGIBILITY REQUIREMENTS

A grant application will be comprised of an individual research project led by a Principal Investigator or co-Principal Investigators. Principal Investigators must be full-time faculty members. Applications that involve collaboration between lab scientist and clinical investigator are desirable but not mandatory.

The Grant application will provide a scientific rationale, project narrative, significance, detailed timeline and budget. Approved grant applications will provide a progress report (2 page limit) at six months and again at 30 days prior to end of year one.

The minimal requirements for the grant applications are:
• A project narrative that explicitly focuses on the genetics, biology, or treatment of TNBC recognizing that TNBC is a unique subtype of breast cancer.
A project narrative that explicitly presents the goals and significance, as well as future potential growth of the overall project.

REQUIRED GRANT APPLICATION COMPONENTS

A complete grant application package must contain all the required items listed in Table 1.

<table>
<thead>
<tr>
<th>Section</th>
<th>Category</th>
<th>Page Limit</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Research Information:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>General Project Information</td>
<td>1</td>
<td>Required. Identifies general project information, the applicant organization, the Project Director, and the Principal Investigators.</td>
</tr>
<tr>
<td>B</td>
<td>Scientific Abstract</td>
<td>2000 characters</td>
<td>Required. This is the scientific description of the project.</td>
</tr>
<tr>
<td>C</td>
<td>Key Personnel</td>
<td>1</td>
<td>Required. Identifies all key personnel.</td>
</tr>
<tr>
<td>D</td>
<td>Long-term Vision</td>
<td>1</td>
<td>Required. Future plans to leverage research results for project growth.</td>
</tr>
<tr>
<td>E</td>
<td>Project Narrative (Specific Aims and Research Plan – Significance, Innovation, and Approach, Timeline)</td>
<td>4</td>
<td>Required.</td>
</tr>
<tr>
<td>F</td>
<td>Literature Cited</td>
<td></td>
<td>Required.</td>
</tr>
<tr>
<td>G</td>
<td>Budget &amp; Budget Justification</td>
<td></td>
<td>Required. The budget must explain the planned spending.</td>
</tr>
<tr>
<td>H</td>
<td>Biographical Sketches</td>
<td>4 per person</td>
<td>Required for all key personnel.</td>
</tr>
<tr>
<td>I</td>
<td>Other Support</td>
<td></td>
<td>Required. NIH format. All other active and pending awards for the Project Director and Principal Investigators.</td>
</tr>
</tbody>
</table>

REVIEW CRITERIA

Applications will be scored on:
1. Innovation;
2. How the science will ultimately translate to human care;
3. Potential for improving cancer treatment outcomes or survivorship.